MIRENA

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Malta, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug MIRENA contains one active pharmaceutical ingredient (API):

1 Levonorgestrel
UNII 5W7SIA7YZW - LEVONORGESTREL

The precise mode of action of levonorgestrel as an emergency contraceptive is not known. At the recommended regimen, levonorgestrel is thought to work mainly by preventing ovulation and fertilisation if intercourse has taken place in the preovulatory phase, when the likelihood of fertilisation is the highest.

Read about Levonorgestrel

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
G02BA03 Plastic IUD with progestogen G Genito urinary system and sex hormones → G02 Other gynecologicals → G02B Contraceptives for topical use → G02BA Intrauterine contraceptives
Discover more medicines within G02BA03
G03AC03 Levonorgestrel G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03A Hormonal contraceptives for systemic use → G03AC Progestogens
Discover more medicines within G03AC03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 8633J
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 538915090024217
Country: CA Health Products and Food Branch Identifier(s): 02243005
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): 30020-10-11
Country: EE Ravimiamet Identifier(s): 1009493
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 63158
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 014453
Country: FR Base de données publique des médicaments Identifier(s): 66349230
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 34933, 374031
Country: HK Department of Health Drug Office Identifier(s): 41251
Country: IE Health Products Regulatory Authority Identifier(s): 33526, 33578
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 3519
Country: JP 医薬品医療機器総合機構 Identifier(s): 2529710X1027
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1012090, 1060572, 1092333, 1092692
Country: MT Medicines Authority Identifier(s): MA639/02201, PI908/05602A
Country: MX Comisión Federal para la Protección contra Riesgos Sanitarios Identifier(s): 259M99
Country: NL Z-Index G-Standaard, PRK Identifier(s): 98590
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 7966
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100157135, 100292360, 100292726, 100324254, 100324691, 100324700, 100326224, 100356610, 100357302, 100359301, 100361309, 100361670, 100384718, 100437515, 100443272, 100455110
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W64655001
Country: SG Health Sciences Authority Identifier(s): 07915P
Country: TN Direction de la Pharmacie et du Médicament Identifier(s): 7243091
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699546326716
Country: US FDA, National Drug Code Identifier(s): 50419-423
Country: ZA Health Products Regulatory Authority Identifier(s): 32/34/0332

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.